Keywords: Licensing, Debiopharm, Novartis, Teva, Active Biotech, Qiagen, Merck & Co, AnaptaysBio, Novavax, ROVI

Licensing deals: Debiopharm/Novartis; Teva/Active Biotech; Qiagen on biomarker; Merck & Co/AnaptysBio; and Novavax/ROVI accord dropped

Article | 9 February 2010

Switzerland’s Debiopharm Group has granted an exclusive, worldwide (excluding Japan) licence to Swiss drug major Novartis for the development, manufacture and commercialization of Debio 025 (alisporivir), a selective, first-in-class cyclophilin (Cyp) inhibitor with a potent anti-hepatitis C virus (HCV) effect. The product is currently in Phase IIb clinical development for the treatment of hepatitis C.

Under the terms of the agreement, Novartis will pay Debiopharm an upfront, development and sales milestones as well as royalties. Enjoying this artcle? To continue reading you need to login, take a FREE trial or subscribe.

30 day FREE trial

Sign up in less than 60 seconds! No payment needed.

Want to read the full article?
Take a 30 day FREE Trial

Take a no obligations 30 day trial.
Only one trial per user. Find out more details

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in